Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, increasing in value.
I'm guessing we see 120
What an ignorant post.
I agree. Shake out some weak hands tomorrow then explode on Wednesday
And how do you know this? Did Tim Cook call you personally?
Yes, you are wrong.
Bob's response to my email asking for clarification on the latest ruling...
"In response to your email The ‘466 patent contains 15 claims, 10 of which are not affected by the Order. The ruling also does not affect other portions of MMR’s health information technology patent portfolio which, dating back to filings in 2005, currently includes 13 U.S. patents (with over 300 issued claims), 18 additional pending U.S. patent applications (with over 300 claims), nine foreign patents, including two in Australia, two in Mexico, with others in New Zealand, Singapore, Japan, South Korea, and Canada, and 25 other pending patent applications in foreign countries. The Court's Order does not affect these other patents."
If that's true, then why weren't claims 1-23 ruled invalid in the last ruling?
Wrong, claims 1-3 ruled invalid. Claims 4-28 valid. Claims 1-3 will be appealed. MMR won the last two appeals. Good try though.
No, it's not a "final judgment." You are mistaken.
Once again, it's not a final judgement and I'm referring to the defendants in this case settling. It's far from over. Walgreens lawyers aren't stupid. The remaining defendants are just stalling for time. MMR has good appeals and it appears they won the last two. Defendants are directed to submit a proposed judgment by January 8. 2015. Anything can happen. Cases could settle to license the rest of the portfolio and any of the defendants could be using this news to buy the company.
"No one else has settled", YET. Key word. The time is approaching. It'll be interesting to see who's right.
Maybe Walgreens needs better lawyers then. Too funny. Good luck to you.
So Walgreens settled because the patents are invalid? LOL, ok. If you say so.
Not worthless. Just one hell of a buying opportunity.
The patents are not invalid as you suggest. That was not a final judgment. The Court's ruling held claims 1-3 of the '883 patent to be invalid. There are a total of 28 claims in the '883 patent, a number of which the company believes are not affected by the Court's Order.
GREAT NEWS, LAST DATE SET FOR SETTLEMENT CONFERENCE & JURY TRIAL IN MYMEDICALRECORDS PATENT LITIGATION CASE
Post Markman Scheduling Order issued on September 18th in Plaintiff MyMedicalRecords V. Defendants Quest Diagnostics, Inc., Jardogs, LLC, Allscripts Healthcare Solutions Inc., WebMD Health Corp. & WebMD Health Services Group Inc. patent litigation. Fact discovery is open through 2/18/2015; last date to conduct settlement conference is 3/18/2015; jury trial set for 5/19/2015 9:00 AM. Everything happening now! MMR is pleased that the Court denied Defendants' request to stay discovery and instead opened discovery and set a jury trial date!
See Facebook
Is this the company that you're referring to? The one he sold for $192.5 million?
http://www.nytimes.com/1999/01/25/business/pint-sized-deal-gave-at-t-a-barrel-s-worth-of-challenges.html
MMR is excited about Celgene’ s recent announcement pertaining to their progress with “follicular lymphoma” using the product “lenalidomide” which is also a subject of MMR’s licensing agreement with Celgene;
CELGENE has announced plans to complete enrollment of its phase III study of lenalidomide plus rituximab in patients with previously untreated disease in the second half of 2014;
http://www.sec.gov/Archives/edgar/data/1285701/000113626111000182/exh10-32.htm
http://ir.celgene.com/releasedetail.cfm?releaseid=866799
"In follicular lymphoma, the company expects to complete enrollment of RELEVANCE, its phase III study of lenalidomide plus rituximab compared with rituximab plus chemotherapy in patients with previously untreated disease in the second half of 2014."
MMRGlobal has received the next Celgene milestone payment. See FaceBook.
Settlements are imminent IMO.
MMR is excited about Celgene’ s recent announcement pertaining to their progress with “follicular lymphoma” using the product “lenalidomide” which is also a subject of MMR’s licensing agreement with Celgene;
CELGENE has announced plans to complete enrollment of its phase III study of lenalidomide plus rituximab in patients with previously untreated disease in the second half of 2014;
http://www.sec.gov/Archives/edgar/data/1285701/000113626111000182/exh10-32.htm
http://ir.celgene.com/releasedetail.cfm?releaseid=866799
"In follicular lymphoma, the company expects to complete enrollment of RELEVANCE, its phase III study of lenalidomide plus rituximab compared with rituximab plus chemotherapy in patients with previously untreated disease in the second half of 2014."
If the markman comes back in MMR's favor, count on it. IMO
Please report back ASAP. Thanks.
Ask that question in one week.
Wal-Mart too will eventually kneel to MMR.
MMRGlobal and Cerner Announce Patent Agreement
LOS ANGELES, CA -- (Marketwired) -- 03/12/14 -- MMRGlobal, Inc. (OTCQB: MMRF) ("MMR") today announced an agreement with Cerner Corporation relating to MMR's MyMedicalRecords, Inc. Personal Health Record patent portfolio, including U.S. Patent Nos. 8,117,045; 8,117,646; 8,121,855; 8,301,466; 8,321,240; 8,352,287; 8,352,288; 8,498,883, 8,626,532 and 8,645,161. The confidential agreement includes other terms and conditions related to an ongoing business relationship between the parties.
MMRGlobal CEO, Robert H. Lorsch stated, "We're pleased to announce this Patent Agreement with Cerner which represents a unique opportunity for Cerner to benefit from MMR's patented intellectual property. MMR is especially proud to have entered into this agreement with an organization that collectively provides solutions to more than 14,000 facilities worldwide including more than 3,000 hospitals and 2,900 physician practices."
MMR's U.S. patent portfolio includes more than 250 issued claims and additional applications and continuation applications. The patents involve inventions pertaining to Personal Health Records, Patient Portals and other Electronic Health Record systems. In addition to its U.S. patents, the Company also has patents issued, pending and/or applied for in 11 other countries or regional authorities of commercial interest including Australia, Singapore, New Zealand, Mexico, Japan, Canada, Hong Kong, China, South Korea, Israel and Europe.
About MMRGlobal
MMRGlobal, Inc., through its wholly-owned subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of the Company's products and services at www.mmrtheater.com.
http://phx.corporate-ir.net/phoenix.zhtml?c=178404&p=irol-newsArticle&ID=1908273&highlight=
Cerner to Acquire Siemens Health Services for $1.3 Billion
August 5, 2014
KANSAS CITY, Mo., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Cerner Corporation (CERN) and Siemens AG today announced they signed a definitive agreement for Cerner to acquire the assets of Siemens' health information technology business unit, Siemens Health Services, for $1.3 billion in cash. By combining investments in R&D, knowledgeable resources, and complementary client bases, the acquisition creates scale for future innovation. As part of the agreement, Cerner and Siemens will form a strategic alliance to bring new solutions to market that combine Cerner's health IT leadership and Siemens' strengths in medical devices and imaging.
"We believe this is an all-win situation for the clients of both organizations and all of our associates and shareholders," said Neal Patterson, Cerner chairman, CEO and co-founder. "Through more than $4 billion of cumulative investments in R&D, Cerner has established a strong market standing and is positioned for continued growth. Siemens' health care IT assets provide additional scale, R&D, an impressive client base, and knowledgeable and experienced associates who will help Cerner achieve our plans for the next decade. In addition, the alliance we're creating will drive the next generation of innovations that embed information from the EMR inside advanced diagnostic and therapeutic technologies, benefitting our shared clients."
Based on 2014 estimates, Cerner and Siemens Health Services have combined totals of more than:
20,000 associates in more than 30 countries
18,000 client facilities, including some of the largest health care organizations in their respective countries
$4.5 billion of annual revenue
$650 million of annual R&D investment
The transaction is expected to be more than $0.15 accretive to Cerner's non-GAAP diluted EPS in 2015, and more than $0.25 accretive in 2016. Non-GAAP earnings are expected to exclude share-based compensation expense, one-time transaction costs, and acquisition-related amortization and deferred revenue adjustments.
"We are excited to join with one of the most competitive companies in health IT today, and a recognized leader in innovation," said John Glaser, Ph.D., CEO of the Health Services business unit of Siemens Healthcare. "Siemens cares deeply about its clients and believes Cerner is the best organization to fully support their health IT needs going forward. The knowledge and strength of our combined resources opens up great possibilities for future collaboration and development, which is exciting for all of us. And our clients will benefit from our alignment with a company that has such a strong historical and future commitment to rapid innovation."
Cerner has a 35-year history of creating value for clients by providing innovative solutions and services that help health care providers around the world increase safety, improve quality and reduce waste. Cerner is well-positioned to help clients be leaders in health care delivery and population health management today and tomorrow. The company's competitive market position, combined with significant investments in R&D, understanding of advances in science and IT, as well as health care regulatory and industry shifts, enable it to help clients succeed.
"We have tremendous respect for Siemens' clients, their markets and their needs," said Patterson. "We look forward to bringing them into the Cerner family, especially as they face increasingly complex clinical and regulatory environments, with mandates to improve quality and pressures to lower cost. We pride ourselves on helping clients navigate changing times so they can be leaders in providing care to their communities. We're committed to supporting Siemens' clients, and we want them to have confidence that we have the vision, scale and resources to help them achieve their plans for building their organizations' futures."
Following the acquisition, support for Siemens Health Services core platforms will remain in place. Current implementations will continue, and Cerner plans to support and advance the Soarian platform for at least the next decade. Cerner will work with all clients to support their short-term and long-term business needs.
Global Alliance
Cerner and Siemens will create a strategic alliance to jointly invest in innovative projects that integrate health IT with medical technologies for the purpose of enhancing workflows and improving clinical outcomes. Each company will contribute up to $50 million to fund projects of shared importance to both companies and their clients.
The alliance has a three-year initial term. Advanced workflows along with medical images and their unique role in diagnostic and therapeutic decision-making, will be an early focus of the joint work.
"Siemens is very innovative around imaging, diagnostic and therapeutic technologies and processes," said Patterson. "Medical technologies generate mountains of images and other data that must be stored, accessed, visualized and interpreted intelligently. In addition, advanced diagnostic and therapeutic processes are enhanced by presenting EMR data at just the right moment and in the right context. Together we will innovate at the edge where IT, processes and technologies meet."
Transaction Summary
Cerner intends to finance the acquisition with cash on hand. The acquisition is expected to close in the first quarter of 2015, subject to regulatory approval and other customary conditions. The transaction has been approved by the boards of Cerner and Siemens.
Greenhill & Co. is acting as financial advisor to Cerner, and Latham & Watkins LLP is acting as its legal counsel. JP Morgan is acting as financial advisor to Siemens, and Clifford Chance LLP is acting as its legal advisor.
Conference Call
Cerner will host a conference call for the investment community to discuss the acquisition at 4p.m. CT on Tuesday, Aug. 5. The dial-in number for the conference call is (617) 614-4909; the passcode is Cerner. Cerner recommends joining the call 15 minutes early for registration. The re-broadcast of the call will be available from 8 p.m. CT, Aug. 5 through 11:59 p.m. CT, Aug. 12. The dial-in number for the re-broadcast is (617) 801-6888; the passcode is 94618496.
A webcast and slides that will be discussed on the call will be available on Cerner's website atwww.cerner.com under the About Cerner section (click Investor Relations, then Presentations and Webcasts).
About Cerner
Cerner's health information technologies connect people, information, and systems, at approximately 14,000 facilities worldwide. Recognized for innovation, Cerner solutions assist clinicians in making care decisions and enable organizations to manage the health of populations. The company provides clients with a wide range of in-house services, as well as an integrated clinical and financial system to help organizations manage revenue. Cerner's mission is to contribute to the systemic improvement of health care delivery and the health of communities. (CERN) For more information about Cerner, please visit www.cerner.com, check out our blog at www.cerner.com/blog and connect with us on Twitter at http://www.twitter.com/cerner and on Facebook atwww.facebook.com/cerner.
Certain trademarks, service marks and logos set forth herein are property of Cerner Corporation and/or its subsidiaries. All other non-Cerner marks are the property of their respective owners.
All statements in this press release that do not directly and exclusively relate to historical facts constitute forward-looking statements. Statements relating to the expected benefits of the proposed transaction and Cerner's post-transaction plans, objectives, expectations and intentions are examples of such forward-looking statements. These forward-looking statements are based on the current beliefs, expectations and assumptions of Cerner's management with respect to future events and are subject to a number of significant risks and uncertainties. It is important to note that Cerner's performance, and actual results, financial condition or business could differ materially from those expressed in such forward-looking statements. In many instances, the words "plans," "estimates," "intends," "believe," "position," "expects," "will" or the negative of these words, variations thereof or similar expressions are intended to identify such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: risks inherent with business acquisitions and integrations such as difficulties and operational and financial risks associated with integrating Cerner and the acquired business; the occurrence of any event, change or other circumstances that could give rise to the termination of the transaction agreements; the risk that the necessary regulatory approvals may not be obtained in a timely manner or may be obtained subject to conditions that are not anticipated; the risk of uncertainty as to timing of the consummation of the acquisition; risks that any of the closing conditions to the proposed transaction may not be satisfied or may not be satisfied in a timely manner; risks related to disruption of management time from ongoing business operations due to the proposed transaction; failure to realize the synergies and other benefits expected from the proposed transaction; risk that the assets and business acquired may not continue to be commercially successful; the effect of the announcement of the proposed transaction and the transaction itself on the ability of Cerner to retain customers and retain and hire key personnel and maintain relationships with key suppliers; unexpected costs, charges or expenses resulting from the transaction; and litigation or claims relating to the transaction or the acquired assets and business. Additional discussion of other risks, uncertainties and factors affecting Cerner's business is contained in Cerner's filings with the Securities and Exchange Commission. The reader should not place undue reliance on forward-looking statements, since the statements speak only as of the date that they are made. Cerner undertakes no obligation to update forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial condition or business over time.
The product is now on drugstore.com
Allscripts is headquartered in Chicago.
New MMRGlobal FaceBook post. Can't repost from my cell phone.
I bought 28K at .0275 and 8K at .027 today if that makes you feel better. Money well spent. IMO
Walgreens wouldn't have settled if they thought they could win in court. Really? LOL
Tell that to Walgreens and Cerner.
How and when did he provide "well thought out plans for when one might occur?"
When did the CEO say anything pertaining to doing a reverse split? Provide a link please.
The settlements will speak for themselves.